Sol­id Bio­sciences ap­pears to be prep­ping for an IPO with $50M round for Duchenne gene ther­a­py

Sol­id Bio­sciences has come up with a $50 mil­lion crossover round that would ap­pear to be po­si­tion­ing the com­pa­ny for an IPO as it ad­vances a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy in­to the clin­ic.

Found­ed by Duchenne dad — and for­mer JP Mor­gan in­vest­ment banker — Ilan Gan­ot, the Cam­bridge, MA-based biotech at­tract­ed RA Cap­i­tal and Bain to the lead roles in the new round. RA is a well known crossover in­vestor while Bain has be­gun to spread its wings with a new fund.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER